It's awesome that this is possible. Right now HIV infections are basically a minor nuisance, provided you're taking the appropriate medication, but this bodes well for future treatment of viral infections.
Even with your caveat, the fact that more than 1 million people died from HIV in 2015 is probably a good signal to not use the term "minor nuisance".
Sucks for the developing world, hopefully we can cure it once and for all.
Idk where you got that number from... From the article you linked, "In the United States, 6,721 people died from HIV and AIDS in 2014". That's out of "An estimated 1.2 million people in the United States were living with HIV at the end of 2013". Since 1/8 people infected with HIV don't know it (and subsequently probably develop full on AIDS and complications), it's fair to say that most of the deaths are due to lack of treatment.
Edit: I see you were talking about worldwide, but that's still out of 36 million people living with HIV in the world.
The cost of treating an HIV+ person in the US is roughly $400K over the course of their expected lifetime. This is more than a nuisance sum. HIV treatment can also significantly affect quality of life.It is not yet time to become blase.
I don't understand how anybody can say that. HIV treatment is extremely heavy and has potentially horrible side effects that must be masked with other drugs that have their share of horrible side effects. This + the fact that many people get only diagnosed when they are terminally ill due to the nature of the disease. I'm not even talking about the cost of the treatment.
Your comment is just horrible, whatever the intent was.
> The Gilead Advancing Access® co-pay coupon card (“Card”) can be used only by eligible residents of the U.S., Puerto Rico, or U.S. territories at participating eligible retail, specialty, or mail-order pharmacies in the U.S., Puerto Rico, or U.S. territories. Product must originate in the U.S., Puerto Rico, or U.S. territories. You must be 18 years or older to use the Card for yourself or a minor.